Sign In
Buy RYTM
$99.25
-6.49 (-6.14%)
At Close: Jul 31, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $358,588.86 in Stock
06:04am, Monday, 09'th Feb 2026
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CFO Hunter Smith sold 3,381 shares of the company's stock in a transaction on Thursday, February 5th. The stock was sold at an average pri
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM
04:49am, Friday, 06'th Feb 2026
Penserra Capital Management LLC bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
08:00am, Thursday, 05'th Feb 2026
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
This High-Flying Growth Stock Is Hiding in Plain Sight
05:52am, Monday, 02'nd Feb 2026
Many investors aren't familiar with Rhythm Pharmaceuticals because of its small size and focus on rare diseases. However, this biotech stock has soared and could rise even more with multiple catalysts
EFG Asset Management North America Corp. Invests $2.05 Million in Rhythm Pharmaceuticals, Inc. $RYTM
06:14am, Wednesday, 28'th Jan 2026
EFG Asset Management North America Corp. acquired a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the third quarter, according to its most recent filing with the SEC. The fund acquired 2
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 prel
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Rhythm Pharmaceuticals, Inc. $RYTM
05:16am, Monday, 05'th Jan 2026
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the third quarter, according to the company in its most recent Form 13F filing with
Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 5.8% during the undefined quarter, according to its most recent Form 13F filing with the SE
Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
03:59am, Saturday, 13'th Dec 2025
Alkeon Capital Management LLC raised its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 24.5% during the undefined quarter, according to its most recent disclosure with the Secur
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster
04:28pm, Thursday, 11'th Dec 2025
Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win
01:49pm, Thursday, 11'th Dec 2025
Rhythm Pharmaceuticals said Thursday said it would send it would send its leading drug into registrational testing for Prader-Willi.
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
01:17pm, Thursday, 11'th Dec 2025
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) stock is higher on Thursday, after the company shared preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi s
-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising re
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
04:01pm, Wednesday, 10'th Dec 2025
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
